![](/img/cover-not-exists.png)
Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG)
S. Aamdal, B. Lund, I. Koier, M. Houten, J. Wanders, J. VerweijVolume:
45
Language:
english
Pages:
4
DOI:
10.1007/pl00006748
Date:
January, 2000
File:
PDF, 78 KB
english, 2000